Melanoma circulating tumor cells: Benefits and challenges required for clinical application

Marsavela, G; Aya-Bonilla, CA; Warkiani, ME; Gray, ES; Ziman, M

Melanoma circulating tumor cells: Benefits and challenges required for clinical application

Marsavela, G Aya-Bonilla, CA Warkiani, ME

Gray, ES Ziman, M

Permalink

Publication Type:: Journal Article
Citation:: Cancer Letters, 2018, 424 pp. 1 - 8
Issue Date:: 2018-06-28

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted Manuscript VersionAdobe PDF (1.28 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Marsavela, G	en_US
dc.contributor.author	Aya-Bonilla, CA	en_US
dc.contributor.author	Warkiani, ME https://orcid.org/0000-0002-4184-1944	en_US
dc.contributor.author	Gray, ES	en_US
dc.contributor.author	Ziman, M	en_US
dc.date.available	2020-05-25T19:15:06Z
dc.date.issued	2018-06-28	en_US
dc.identifier.citation	Cancer Letters, 2018, 424 pp. 1 - 8	en_US
dc.identifier.issn	0304-3835	en_US
dc.identifier.uri	http://hdl.handle.net/10453/132163
dc.description.abstract	© 2018 The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.	en_US
dc.relation.ispartof	Cancer Letters	en_US
dc.relation.isbasedon	10.1016/j.canlet.2018.03.013	en_US
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.classification	Oncology & Carcinogenesis	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Melanoma	en_US
dc.subject.mesh	Cell Separation	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Male	en_US
dc.subject.mesh	Neoplastic Cells, Circulating	en_US
dc.subject.mesh	Biomarkers, Tumor	en_US
dc.title	Melanoma circulating tumor cells: Benefits and challenges required for clinical application	en_US
dc.type	Journal Article
utslib.citation.volume	424	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	open_access	*
pubs.publication-status	Published	en_US
pubs.volume	424	en_US

Abstract:

© 2018 The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/132163